Click for best price
Hormone Refractory Prostate Cancer HRPCA Market Size, Share 2023
Hormone Refractory Prostate Cancer (HRPCA) or Castrate-Resistant Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after having hormonal Therapy, is now under the spotlight in prostate cancer market. Due to the high unmet clinical need associated with limited survival periods, intensifying HRPCA prevalence and fast-emerging treatment modifications, the global HRPCA market is poised to witness an unprecedented growth.
This report aims to provide a comprehensive presentation of the global market for Hormone Refractory Prostate Cancer (HRPCA), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hormone Refractory Prostate Cancer (HRPCA). This report contains market size and forecasts of Hormone Refractory Prostate Cancer (HRPCA) in global, including the following market information:
Global Hormone Refractory Prostate Cancer (HRPCA) Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Hormone Refractory Prostate Cancer (HRPCA) market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Cytotoxic Agents Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Hormone Refractory Prostate Cancer (HRPCA) include Astellas Inc, Sanofi S.A, Dendreon Corporation, Bayer AG and Johnson & Johnson, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Hormone Refractory Prostate Cancer (HRPCA) companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Hormone Refractory Prostate Cancer (HRPCA) Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Hormone Refractory Prostate Cancer (HRPCA) Market Segment Percentages, by Type, 2022 (%)
Cytotoxic Agents
Anti-Androgens
Vaccines
Radio-Pharmaceuticals
Global Hormone Refractory Prostate Cancer (HRPCA) Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Hormone Refractory Prostate Cancer (HRPCA) Market Segment Percentages, by Application, 2022 (%)
Hospitals
Ambulatory Surgical Centers
Specialty Clinics
Others
Global Hormone Refractory Prostate Cancer (HRPCA) Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Hormone Refractory Prostate Cancer (HRPCA) Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Hormone Refractory Prostate Cancer (HRPCA) revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Hormone Refractory Prostate Cancer (HRPCA) revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Astellas Inc
Sanofi S.A
Dendreon Corporation, Bayer AG
Johnson & Johnson
Outline of Major Chapters:
Chapter 1: Introduces the definition of Hormone Refractory Prostate Cancer (HRPCA), market overview.
Chapter 2: Global Hormone Refractory Prostate Cancer (HRPCA) market size in revenue.
Chapter 3: Detailed analysis of Hormone Refractory Prostate Cancer (HRPCA) company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Hormone Refractory Prostate Cancer (HRPCA) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Hormone Refractory Prostate Cancer (HRPCA) Market, Global Outlook and Forecast 2023-2029 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2022 |
| Forecast Year |
2030 |
| Number of Pages |
68 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Hormone Refractory Prostate Cancer (HRPCA) Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Hormone Refractory Prostate Cancer (HRPCA) Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Hormone Refractory Prostate Cancer (HRPCA) Overall Market Size
2.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size: 2022 VS 2029
2.2 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Hormone Refractory Prostate Cancer (HRPCA) Players in Global Market
3.2 Top Global Hormone Refractory Prostate Cancer (HRPCA) Companies Ranked by Revenue
3.3 Global Hormone Refractory Prostate Cancer (HRPCA) Revenue by Companies
3.4 Top 3 and Top 5 Hormone Refractory Prostate Cancer (HRPCA) Companies in Global Market, by Revenue in 2022
3.5 Global Companies Hormone Refractory Prostate Cancer (HRPCA) Product Type
3.6 Tier 1, Tier 2 and Tier 3 Hormone Refractory Prostate Cancer (HRPCA) Players in Global Market
3.6.1 List of Global Tier 1 Hormone Refractory Prostate Cancer (HRPCA) Companies
3.6.2 List of Global Tier 2 and Tier 3 Hormone Refractory Prostate Cancer (HRPCA) Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Markets, 2022 & 2029
4.1.2 Cytotoxic Agents
4.1.3 Anti-Androgens
4.1.4 Vaccines
4.1.5 Radio-Pharmaceuticals
4.2 By Type - Global Hormone Refractory Prostate Cancer (HRPCA) Revenue & Forecasts
4.2.1 By Type - Global Hormone Refractory Prostate Cancer (HRPCA) Revenue, 2018-2023
4.2.2 By Type - Global Hormone Refractory Prostate Cancer (HRPCA) Revenue, 2024-2029
4.2.3 By Type - Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Hormone Refractory Prostate Cancer (HRPCA) Market Size, 2022 & 2029
5.1.2 Hospitals
5.1.3 Ambulatory Surgical Centers
5.1.4 Specialty Clinics
5.1.5 Others
5.2 By Application - Global Hormone Refractory Prostate Cancer (HRPCA) Revenue & Forecasts
5.2.1 By Application - Global Hormone Refractory Prostate Cancer (HRPCA) Revenue, 2018-2023
5.2.2 By Application - Global Hormone Refractory Prostate Cancer (HRPCA) Revenue, 2024-2029
5.2.3 By Application - Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region - Global Hormone Refractory Prostate Cancer (HRPCA) Market Size, 2022 & 2029
6.2 By Region - Global Hormone Refractory Prostate Cancer (HRPCA) Revenue & Forecasts
6.2.1 By Region - Global Hormone Refractory Prostate Cancer (HRPCA) Revenue, 2018-2023
6.2.2 By Region - Global Hormone Refractory Prostate Cancer (HRPCA) Revenue, 2024-2029
6.2.3 By Region - Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country - North America Hormone Refractory Prostate Cancer (HRPCA) Revenue, 2018-2029
6.3.2 US Hormone Refractory Prostate Cancer (HRPCA) Market Size, 2018-2029
6.3.3 Canada Hormone Refractory Prostate Cancer (HRPCA) Market Size, 2018-2029
6.3.4 Mexico Hormone Refractory Prostate Cancer (HRPCA) Market Size, 2018-2029
6.4 Europe
6.4.1 By Country - Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue, 2018-2029
6.4.2 Germany Hormone Refractory Prostate Cancer (HRPCA) Market Size, 2018-2029
6.4.3 France Hormone Refractory Prostate Cancer (HRPCA) Market Size, 2018-2029
6.4.4 U.K. Hormone Refractory Prostate Cancer (HRPCA) Market Size, 2018-2029
6.4.5 Italy Hormone Refractory Prostate Cancer (HRPCA) Market Size, 2018-2029
6.4.6 Russia Hormone Refractory Prostate Cancer (HRPCA) Market Size, 2018-2029
6.4.7 Nordic Countries Hormone Refractory Prostate Cancer (HRPCA) Market Size, 2018-2029
6.4.8 Benelux Hormone Refractory Prostate Cancer (HRPCA) Market Size, 2018-2029
6.5 Asia
6.5.1 By Region - Asia Hormone Refractory Prostate Cancer (HRPCA) Revenue, 2018-2029
6.5.2 China Hormone Refractory Prostate Cancer (HRPCA) Market Size, 2018-2029
6.5.3 Japan Hormone Refractory Prostate Cancer (HRPCA) Market Size, 2018-2029
6.5.4 South Korea Hormone Refractory Prostate Cancer (HRPCA) Market Size, 2018-2029
6.5.5 Southeast Asia Hormone Refractory Prostate Cancer (HRPCA) Market Size, 2018-2029
6.5.6 India Hormone Refractory Prostate Cancer (HRPCA) Market Size, 2018-2029
6.6 South America
6.6.1 By Country - South America Hormone Refractory Prostate Cancer (HRPCA) Revenue, 2018-2029
6.6.2 Brazil Hormone Refractory Prostate Cancer (HRPCA) Market Size, 2018-2029
6.6.3 Argentina Hormone Refractory Prostate Cancer (HRPCA) Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue, 2018-2029
6.7.2 Turkey Hormone Refractory Prostate Cancer (HRPCA) Market Size, 2018-2029
6.7.3 Israel Hormone Refractory Prostate Cancer (HRPCA) Market Size, 2018-2029
6.7.4 Saudi Arabia Hormone Refractory Prostate Cancer (HRPCA) Market Size, 2018-2029
6.7.5 UAE Hormone Refractory Prostate Cancer (HRPCA) Market Size, 2018-2029
7 Hormone Refractory Prostate Cancer (HRPCA) Companies Profiles
7.1 Astellas Inc
7.1.1 Astellas Inc Company Summary
7.1.2 Astellas Inc Business Overview
7.1.3 Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Major Product Offerings
7.1.4 Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Revenue in Global Market (2018-2023)
7.1.5 Astellas Inc Key News & Latest Developments
7.2 Sanofi S.A
7.2.1 Sanofi S.A Company Summary
7.2.2 Sanofi S.A Business Overview
7.2.3 Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Major Product Offerings
7.2.4 Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Revenue in Global Market (2018-2023)
7.2.5 Sanofi S.A Key News & Latest Developments
7.3 Dendreon Corporation, Bayer AG
7.3.1 Dendreon Corporation, Bayer AG Company Summary
7.3.2 Dendreon Corporation, Bayer AG Business Overview
7.3.3 Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Major Product Offerings
7.3.4 Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Revenue in Global Market (2018-2023)
7.3.5 Dendreon Corporation, Bayer AG Key News & Latest Developments
7.4 Johnson & Johnson
7.4.1 Johnson & Johnson Company Summary
7.4.2 Johnson & Johnson Business Overview
7.4.3 Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Major Product Offerings
7.4.4 Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Revenue in Global Market (2018-2023)
7.4.5 Johnson & Johnson Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Hormone Refractory Prostate Cancer (HRPCA) Market Opportunities & Trends in Global Market
Table 2. Hormone Refractory Prostate Cancer (HRPCA) Market Drivers in Global Market
Table 3. Hormone Refractory Prostate Cancer (HRPCA) Market Restraints in Global Market
Table 4. Key Players of Hormone Refractory Prostate Cancer (HRPCA) in Global Market
Table 5. Top Hormone Refractory Prostate Cancer (HRPCA) Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Companies, 2018-2023
Table 8. Global Companies Hormone Refractory Prostate Cancer (HRPCA) Product Type
Table 9. List of Global Tier 1 Hormone Refractory Prostate Cancer (HRPCA) Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Hormone Refractory Prostate Cancer (HRPCA) Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Hormone Refractory Prostate Cancer (HRPCA) Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Hormone Refractory Prostate Cancer (HRPCA) Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Hormone Refractory Prostate Cancer (HRPCA) Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application ? Global Hormone Refractory Prostate Cancer (HRPCA) Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Hormone Refractory Prostate Cancer (HRPCA) Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Hormone Refractory Prostate Cancer (HRPCA) Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region ? Global Hormone Refractory Prostate Cancer (HRPCA) Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Hormone Refractory Prostate Cancer (HRPCA) Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Hormone Refractory Prostate Cancer (HRPCA) Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Hormone Refractory Prostate Cancer (HRPCA) Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Hormone Refractory Prostate Cancer (HRPCA) Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Hormone Refractory Prostate Cancer (HRPCA) Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Hormone Refractory Prostate Cancer (HRPCA) Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Hormone Refractory Prostate Cancer (HRPCA) Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Hormone Refractory Prostate Cancer (HRPCA) Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue, (US$, Mn), 2024-2029
Table 30. Astellas Inc Company Summary
Table 31. Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Product Offerings
Table 32. Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Revenue (US$, Mn) & (2018-2023)
Table 33. Astellas Inc Key News & Latest Developments
Table 34. Sanofi S.A Company Summary
Table 35. Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Product Offerings
Table 36. Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Revenue (US$, Mn) & (2018-2023)
Table 37. Sanofi S.A Key News & Latest Developments
Table 38. Dendreon Corporation, Bayer AG Company Summary
Table 39. Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Product Offerings
Table 40. Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Revenue (US$, Mn) & (2018-2023)
Table 41. Dendreon Corporation, Bayer AG Key News & Latest Developments
Table 42. Johnson & Johnson Company Summary
Table 43. Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Product Offerings
Table 44. Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Revenue (US$, Mn) & (2018-2023)
Table 45. Johnson & Johnson Key News & Latest Developments
List of Figures
Figure 1. Hormone Refractory Prostate Cancer (HRPCA) Segment by Type in 2022
Figure 2. Hormone Refractory Prostate Cancer (HRPCA) Segment by Application in 2022
Figure 3. Global Hormone Refractory Prostate Cancer (HRPCA) Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Hormone Refractory Prostate Cancer (HRPCA) Revenue in 2022
Figure 8. By Type - Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share, 2018-2029
Figure 9. By Application - Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share, 2018-2029
Figure 10. By Type - Global Hormone Refractory Prostate Cancer (HRPCA) Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share, 2018-2029
Figure 12. By Application - Global Hormone Refractory Prostate Cancer (HRPCA) Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share, 2018-2029
Figure 14. By Region - Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share, 2018-2029
Figure 15. By Country - North America Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share, 2018-2029
Figure 16. US Hormone Refractory Prostate Cancer (HRPCA) Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Hormone Refractory Prostate Cancer (HRPCA) Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Hormone Refractory Prostate Cancer (HRPCA) Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share, 2018-2029
Figure 20. Germany Hormone Refractory Prostate Cancer (HRPCA) Revenue, (US$, Mn), 2018-2029
Figure 21. France Hormone Refractory Prostate Cancer (HRPCA) Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Hormone Refractory Prostate Cancer (HRPCA) Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Hormone Refractory Prostate Cancer (HRPCA) Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Hormone Refractory Prostate Cancer (HRPCA) Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Hormone Refractory Prostate Cancer (HRPCA) Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Hormone Refractory Prostate Cancer (HRPCA) Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share, 2018-2029
Figure 28. China Hormone Refractory Prostate Cancer (HRPCA) Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Hormone Refractory Prostate Cancer (HRPCA) Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Hormone Refractory Prostate Cancer (HRPCA) Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Hormone Refractory Prostate Cancer (HRPCA) Revenue, (US$, Mn), 2018-2029
Figure 32. India Hormone Refractory Prostate Cancer (HRPCA) Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share, 2018-2029
Figure 34. Brazil Hormone Refractory Prostate Cancer (HRPCA) Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Hormone Refractory Prostate Cancer (HRPCA) Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share, 2018-2029
Figure 37. Turkey Hormone Refractory Prostate Cancer (HRPCA) Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Hormone Refractory Prostate Cancer (HRPCA) Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Hormone Refractory Prostate Cancer (HRPCA) Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Hormone Refractory Prostate Cancer (HRPCA) Revenue, (US$, Mn), 2018-2029
Figure 41. Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
